David L Stevens
Overview
Explore the profile of David L Stevens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
753
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang B, Ma H, Pagare P, Li M, Mendez R, Gillespie J, et al.
ACS Pharmacol Transl Sci
. 2024 Dec;
7(12):4165-4182.
PMID: 39698260
The development of highly potent and selective μ opioid receptor (MOR) modulators with favorable drug-like properties has always been a focus in the opioid domain. Our previous efforts led to...
2.
M St Onge C, Pagare P, Zheng Y, Arriaga M, Stevens D, Mendez R, et al.
J Med Chem
. 2024 May;
67(11):9552-9574.
PMID: 38814086
Despite the availability of numerous pain medications, the current array of Food and Drug Administration-approved options falls short in adequately addressing pain states for numerous patients and consequently worsens the...
3.
Li M, Pagare P, Ma H, M St Onge C, Mendez R, Gillespie J, et al.
J Med Chem
. 2023 Dec;
67(1):603-619.
PMID: 38156970
While there are approved therapeutics to treat opioid overdoses, the need for treatments to reverse overdoses due to ultrapotent fentanyls remains unmet. This may be due in part to an...
4.
Varshneya N, Hassanien S, Holt M, Stevens D, Layle N, Bassman J, et al.
Pharmacol Biochem Behav
. 2023 May;
226:173572.
PMID: 37236405
Opioid overdoses, particularly those involving fentanyl-related substances (FRS), present a significant public health challenge in the United States. This structure-activity relationship (SAR) study evaluated the relationship between the chemical structure...
5.
Ma H, Pagare P, Li M, Neel L, Mendez R, Gillespie J, et al.
J Med Chem
. 2022 Dec;
66(1):577-595.
PMID: 36538027
The search for selective opioid ligands with desired pharmacological potency and improved safety profile has always been an area of interest. Our previous effort yielded a potent opioid modulator, NAN,...
6.
Li M, Stevens D, Arriaga M, Townsend E, Mendez R, Blajkevch N, et al.
ACS Chem Neurosci
. 2022 Nov;
13(24):3608-3628.
PMID: 36449691
Discovery of analgesics void of abuse liability is critical to battle the opioid crisis in the United States. Among many strategies to achieve this goal, targeting more than one opioid...
7.
Varshneya N, Walentiny D, Stevens D, Walker T, Akinfiresoye L, Beardsley P
Pharmacol Biochem Behav
. 2022 Nov;
222:173496.
PMID: 36435268
Synthetic narcotics have been implicated as the single greatest contributor to increases in opioid-related fatalities in recent years. This study evaluated the effects of nine fentanyl-related substances that have emerged...
8.
Pagare P, Li M, Zheng Y, Kulkarni A, Obeng S, Huang B, et al.
J Med Chem
. 2022 Mar;
65(6):5095-5112.
PMID: 35255685
The μ opioid receptor (MOR) has been an intrinsic target to develop treatment of opioid use disorders (OUD). Herein, we report our efforts on developing centrally acting MOR antagonists by...
9.
Huang B, Li M, Klongkumnuankarn P, Mendez R, Gillespie J, Stevens D, et al.
J Med Chem
. 2022 Mar;
65(6):4991-5003.
PMID: 35255683
Opioid-induced constipation (OIC) is a common adverse effect of opioid analgesics. Peripherally acting μ opioid receptor antagonists (PAMORAs) can be applied in the treatment of OIC without compromising the analgesic...
10.
Sierra S, Muchhala K, Jessup D, Contreras K, Shah U, Stevens D, et al.
Neuropharmacology
. 2022 Feb;
209:108988.
PMID: 35183539
Opioids are among the most effective analgesics and the mainstay of pain management. However, concerns about safety and abuse liability have challenged their widespread use by the medical community. Opioid-sparing...